Purpose of the development: Polymyxin B - cyclopeptide antibiotic for the treatment of infections caused by pathogenic Gram-negative organisms Pseudomonas aeruginosa, Klebsiella pneumoniae, Salmonella and other bacteria that are resistant to known antibiotics. Polymyxin B is also used to treat patients in a state of toxic shock induced by the above bacteria and toxins for preparative isolation, with which it is complexed.

Recommended application field: Medicine.

Advantages over analogues: Highly effective preparation.

The development stage readiness: Ready for application

Description of the development:
()
Polymyxin B is less toxic compared to other polymyxins , and can therefore be administered intramuscularly. With the help of genetic selection of highly prepared , bezslizistye fagorezistentnye strains and Bacillus polymyxa, which can be used in the industrial production of polymyxin B. A fermentation medium for maximum educational culture antibiotic within 72 hours of cultivation in industrial fermenter. The ratio of components B1, B2 and B3 in the purified preparation of polymyxin B, and its activity is consistent with the standard regulations.

Information about newness of the development:

ноу-хау--
1 шт.

corresponds technical description
Guarantees stable results getting

Possibility of transfer abroad:
Licence's sale
Licence's sale
Technological document's sale
Creation of joint enterprise
Realization of finished commodity

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua